Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 168

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Anti-NMDAR encephalitis: A single-center, longitudinal study in China

Open access
Xu, Xiaolu, Lu, Qiang, Huang, Yan, Fan, Siyuan, Zhou, Lixin, Yuan, Jing, Yang, Xunzhe, Ren, Haitao, Sun, Dawei, Dai, Yi, Zhu, Huadong, Jiang, Yinan, Zhu, Yicheng, Peng, Bin, Cui, Liying, Guan, Hongzhi · 2020 · Neurology Neuroimmunology & Neuroinflammation

Abstract

OBJECTIVE: To describe the detailed clinical characteristics, immunotherapy, and long-term outcomes of patients with anti-NMDA receptor (NMDAR) encephalitis in China. METHODS: A single-center, prospective study. Patients who met the diagnostic criteria were enrolled from 2011 to 2017 and followed up. The clinical features, treatment, and long-term outcomes were collected prospectively. Factors affecting the long-term prognosis were analyzed. RESULTS: The study included 220 patients. The most common clinical presentations were psychosis (82.7%) and seizures (80.9%). Of the patients, 19.5% had an underlying neoplasm; of which ovarian teratoma was 100% of tumors in females and only one male had lung cancer. Most patients (99.5%) received first-line therapy (glucocorticoids, IV immunoglobulin, or plasmapheresis alone or combined), and only 7.3% received second-line immunotherapy (rituximab, cyclophosphamide alone, or combined). Long-term immunotherapy (mycophenolate mofetil or azathioprine >1 year) was administered to 53.2% of patients. During the first 12 months, 207 (94.1%) patients experienced improvement, and 5 (2.3%) died, whereas 38 (17.3%) experienced relapses. At 12-month follow-up, 92.7% had favorable clinical outcomes (modified Rankin Scale score ≤2). CONCLUSIONS: Patients in China present with psychosis and seizure frequently but have a low percentage of underlying neoplasms. Re-enforced first-line immunotherapy is effective in managing anti-NMDAR encephalitis in the acute phase. Although relapse is relatively common, with combined first-line and long-term immunotherapy, most patients reached favorable outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/nxi.0000000000000633

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 168

Metadata

Authors
Xu, X., Lu, Q., Huang, Y., Fan, S., Zhou, L., Yuan, J., Yang, X., Ren, H., Sun, D., Dai, Y., Zhu, H., Jiang, Y., Zhu, Y., Peng, B., Cui, L., & Guan, H.
Venue
Neurology Neuroimmunology & Neuroinflammation
Published
2020-01
Volume
7
Issue
1
ISSN
2332-7812 (ISSN-L)
OpenAlex
W2980350220
Cited by
168
References
5
FWCI
11.43
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-NMDAR encephalitis: A single-center, longitudinal study in China. https://app.cochat.ai/papers/10.1212/nxi.0000000000000633
The paper
Xu, X., Lu, Q., Huang, Y., Fan, S., Zhou, L., Yuan, J., Yang, X., Ren, H., Sun, D., Dai, Y., Zhu, H., Jiang, Y., Zhu, Y., Peng, B., Cui, L., & Guan, H. (2020). Anti-NMDAR encephalitis: A single-center, longitudinal study in China. Neurology Neuroimmunology & Neuroinflammation. https://doi.org/10.1212/nxi.0000000000000633

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.